Methods of treating, inhibiting, or ameliorating gout, including chronic
acute (refractory) gout, pseudogout, or drug-induced gout, in a human
subject in need thereof, comprising administering to a subject in need a
therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the
incidence of a gout flare is reduced or inhibited.